HIV-associated Lipodystrophy Syndrome: A Review of Clinical Aspects
Approximately two years after the introduction of highly active antiretroviral therapy for the treatment of HIV infection, body shape changes and metabolic abnormalities were increasingly observed. Initially, these were ascribed to protease inhibitors, but it is now clear that nucleoside reverse tra...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2005-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2005/303141 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556420727308288 |
|---|---|
| author | Jean-Guy Baril Patrice Junod Roger LeBlanc Harold Dion Rachel Therrien François Laplante Julian Falutz Pierre Côté Marie-Nicole Hébert Richard Lalonde Normand Lapointe Dominic Lévesque Lyse Pinault Danielle Rouleau Cécile Tremblay Benoît Trottier Sylvie Trottier Chris Tsoukas Karl Weiss |
| author_facet | Jean-Guy Baril Patrice Junod Roger LeBlanc Harold Dion Rachel Therrien François Laplante Julian Falutz Pierre Côté Marie-Nicole Hébert Richard Lalonde Normand Lapointe Dominic Lévesque Lyse Pinault Danielle Rouleau Cécile Tremblay Benoît Trottier Sylvie Trottier Chris Tsoukas Karl Weiss |
| author_sort | Jean-Guy Baril |
| collection | DOAJ |
| description | Approximately two years after the introduction of highly active antiretroviral therapy for the treatment of HIV infection, body shape changes and metabolic abnormalities were increasingly observed. Initially, these were ascribed to protease inhibitors, but it is now clear that nucleoside reverse transcriptase inhibitors also contribute to lipodystrophy syndrome. The syndrome groups together clinical conditions describing changes in body fat distribution that include lipoatrophy, lipoaccumulation or both. However, there does not appear to be a direct link between lipoatrophy and lipoaccumulation that would support a single mechanism for the redistribution of body fat. Currently, there is no clear definition of lipodystrophy, which explains the difficulty in determining its prevalence and etiology. There are no current guidelines for the treatment of fat distribution abnormalities that occur in the absence of other metabolic complications. The present article reviews the current state of knowledge of the definition, symptoms, risk factors, pathogenesis, diagnosis and treatment of the morphological changes associated with lipodystrophy syndrome. |
| format | Article |
| id | doaj-art-f96f8008381a4f4a87b21fcec87e83c7 |
| institution | Kabale University |
| issn | 1712-9532 |
| language | English |
| publishDate | 2005-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-f96f8008381a4f4a87b21fcec87e83c72025-02-03T05:45:31ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95322005-01-0116423324310.1155/2005/303141HIV-associated Lipodystrophy Syndrome: A Review of Clinical AspectsJean-Guy Baril0Patrice Junod1Roger LeBlanc2Harold Dion3Rachel Therrien4François Laplante5Julian Falutz6Pierre Côté7Marie-Nicole Hébert8Richard Lalonde9Normand Lapointe10Dominic Lévesque11Lyse Pinault12Danielle Rouleau13Cécile Tremblay14Benoît Trottier15Sylvie Trottier16Chris Tsoukas17Karl Weiss18Clinique médicale du Quartier Latin, Montréal, Québec, CanadaClinique médicale du Quartier Latin, Montréal, Québec, CanadaClinique Golberg, LeBlanc et Rosengren, Montréal, Québec, CanadaClinique médicale L’Actuel, Montréal, Québec, CanadaUHRESS, CHUM, Hôpital-Dieu de Montréal, Montréal, Québec, CanadaClinique médicale du Quartier Latin, Montréal, Québec, CanadaUHRESS, McGill University Health Centre, Montreal General Hospital, Montréal, Québec, CanadaClinique médicale du Quartier Latin, Montréal, Québec, CanadaService de lutte contre les infections transmissibles sexuellement par le sang, ministère de la Santé et des Services sociaux, Montréal, Québec, CanadaUHRESS, McGill University Health Centre, Royal Victoria Hospital, Montréal, Québec, CanadaUHRESS, Hôpital Sainte-Justine, Centre maternel et infantile sur le sida, Montréal, Québec, CanadaComité des personnes atteintes du VIH du Québec, Montréal, Québec, CanadaCoalition des organismes communautaires québécois de lutte contre le sida, Montréal, Québec, CanadaUHRESS, CHUM, Hôpital Saint-Luc and Hôpital Notre-Dame, Montréal, Québec, CanadaUHRESS, CHUM, Hôpital-Dieu de Montréal, Montréal, Québec, CanadaUnité hospitalière de recherche, d’enseignement et de soin sur le sida (UHRESS), Centre hospitalier de l’Université de Montréal (CHUM), Hôpital Saint-Luc, Montréal, Québec, CanadaUHRESS, Centre hospitalier universitaire de Québec, Montréal, Québec, CanadaUHRESS, McGill University Health Centre, Montreal General Hospital, Montréal, Québec, CanadaAssociation des médecins microbiologistes infectiologues du Québec, Hôpital Maisonneuve-Rosemont, Montréal, Québec, CanadaApproximately two years after the introduction of highly active antiretroviral therapy for the treatment of HIV infection, body shape changes and metabolic abnormalities were increasingly observed. Initially, these were ascribed to protease inhibitors, but it is now clear that nucleoside reverse transcriptase inhibitors also contribute to lipodystrophy syndrome. The syndrome groups together clinical conditions describing changes in body fat distribution that include lipoatrophy, lipoaccumulation or both. However, there does not appear to be a direct link between lipoatrophy and lipoaccumulation that would support a single mechanism for the redistribution of body fat. Currently, there is no clear definition of lipodystrophy, which explains the difficulty in determining its prevalence and etiology. There are no current guidelines for the treatment of fat distribution abnormalities that occur in the absence of other metabolic complications. The present article reviews the current state of knowledge of the definition, symptoms, risk factors, pathogenesis, diagnosis and treatment of the morphological changes associated with lipodystrophy syndrome.http://dx.doi.org/10.1155/2005/303141 |
| spellingShingle | Jean-Guy Baril Patrice Junod Roger LeBlanc Harold Dion Rachel Therrien François Laplante Julian Falutz Pierre Côté Marie-Nicole Hébert Richard Lalonde Normand Lapointe Dominic Lévesque Lyse Pinault Danielle Rouleau Cécile Tremblay Benoît Trottier Sylvie Trottier Chris Tsoukas Karl Weiss HIV-associated Lipodystrophy Syndrome: A Review of Clinical Aspects Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | HIV-associated Lipodystrophy Syndrome: A Review of Clinical Aspects |
| title_full | HIV-associated Lipodystrophy Syndrome: A Review of Clinical Aspects |
| title_fullStr | HIV-associated Lipodystrophy Syndrome: A Review of Clinical Aspects |
| title_full_unstemmed | HIV-associated Lipodystrophy Syndrome: A Review of Clinical Aspects |
| title_short | HIV-associated Lipodystrophy Syndrome: A Review of Clinical Aspects |
| title_sort | hiv associated lipodystrophy syndrome a review of clinical aspects |
| url | http://dx.doi.org/10.1155/2005/303141 |
| work_keys_str_mv | AT jeanguybaril hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT patricejunod hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT rogerleblanc hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT harolddion hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT racheltherrien hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT francoislaplante hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT julianfalutz hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT pierrecote hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT marienicolehebert hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT richardlalonde hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT normandlapointe hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT dominiclevesque hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT lysepinault hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT daniellerouleau hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT ceciletremblay hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT benoittrottier hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT sylvietrottier hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT christsoukas hivassociatedlipodystrophysyndromeareviewofclinicalaspects AT karlweiss hivassociatedlipodystrophysyndromeareviewofclinicalaspects |